It is unclear if a sustained response to the first advanced therapy affects the long-term risk of hospitalization in patients with inflammatory bowel disease (IBD). We have undertaken a retrospective analysis of clinical outcomes using the National Institute for Health and Care Research (NIHR) IBD BioResource database.

Ileocolic resections (ICRs) are the most common resections for Crohn's disease. Historical control groups have often been used for comparison when assessing postoperative recurrence, usually with temporal bias. This study aimed to (1) report contemporary rates of postoperative recurrence requiring repeat surgery (surgical recurrence at anastomosis [surgical recurrence at the ileocolic resection site (SR-ICR)] or surgical recurrence at any site) and the rates of endoscopic recurrence (ER) in the "biologic era"; and (2) determine risk factors for SR-ICR and ER.

Despite advances in therapeutic strategies, postoperative recurrence (POR) of Crohn's disease (CD) remains common, underscoring the importance of vigilant and accurate surveillance. Colonoscopy is the gold standard to assess for POR, but it is invasive and can be poorly tolerated by patients. Intestinal ultrasound (IUS) has emerged as a reliable, noninvasive modality for monitoring CD at the point of care and has excellent accuracy for evaluation of POR. However, visualization of the ileocolic anastomosis with IUS can be challenging. This review provides practical guidance for identifying the ileocolic anastomosis and its key sonographic landmarks. It also outlines techniques for assessing the anastomosis with grayscale IUS and discusses strategies for integrating IUS into routine postoperative surveillance of CD.

Mesalamine (5-aminosalicylic acid, [5-ASA]) is the first-line therapeutic agent in mild-to-moderate ulcerative colitis (UC). The continuous use of 5-ASA involves costs, adverse effects, and delayed treatment escalation. In certain circumstances, such as in patients with Crohn disease (CD) or patients escalated to advanced therapies, discontinuation of 5-ASA may be feasible. However, the implications of withdrawal on disease outcomes remain unclear.

Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), have complex pathologies requiring precise diagnostic tools. We evaluated the clinical utility of anti-integrin αvβ6 antibodies in diagnosing UC, focusing on differences between a U.S. cohort (self-reported White) and a Japanese cohort, and additionally assessed whether combining anti-αvβ6 with anti-EPCR improved diagnostic performance.

Older adults with ulcerative colitis (UC) have unique treatment challenges. Ozanimod is approved for the treatment of moderately to severely active UC in adults based on the phase 3 True North (TN) study results. Here, we analyzed the impact of patient age on ozanimod safety and efficacy in TN and during the open-label extension (OLE).

Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear.

Diet impacts symptoms and inflammation in inflammatory bowel disease (IBD), but limited food access restricts options and hampers adherence to diets that may help in the management of IBD. This study aims to measure the prevalence of food insecurity and characterize its risk factors in the adult population across the United States.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing and remitting mucosal inflammation of the colon. While active UC mucosa is characterized by dysregulated B cell responses and increased B cell and IgG plasma cell populations, targeting CD20-expressing B cells in UC has proven ineffective.

Systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD) are both categorized as autoimmune disorders and have similar non-specific gastrointestinal symptoms. SLE and IBD have shown shared genetic architecture in European ancestry; however, given the ancestry-specificity of genetic architecture, the shared genetic structure in East Asian ancestry remains unclear. This study reveals significant global and local genetic overlap between SLE and IBD subtypes in East Asian ancestry by using genetic correlation analyses. Cross-trait and colocalization analyses identify 64 shared loci and 19 causal variant credible sets between SLE and IBD subtypes. Notably, pleiotropic genes (HIC2, UBE2L3, ARAP1, ATG16L2, ANKS1A, and TULP1) were validated through Gene Expression Omnibus databases and previous studies. The major histocompatibility complex region emerges as a critical hub for shared genetic correlations and pleiotropic effects in SLE-IBD pathogenesis. Gene-level enrichment analyses implicate chemokine and lipid binding as underlying shared biological mechanisms.

In Crohn's disease (CD) patients treated with biologics preoperatively, the optimal strategy for postoperative biologic management remains unclear.

The term "incomplete microscopic colitis" (MCi) has been suggested to define patients with chronic watery diarrhea not fulfilling the complete histologic criteria for MC. There are inconsistent data on the epidemiology of MCi and the optimal management of these patients.

Pediatric Inflammatory Bowel Disease (IBD) is a chronic condition characterized by persistent intestinal inflammation in children. It often presents with distinct clinical phenotypes and is more frequently linked to rare monogenic variants affecting epithelial barrier function or mucosal immunity. Although over 100 genes are associated with monogenic IBD, their roles in the intestinal epithelium remain poorly defined. This study aimed to improve our understanding of epithelial dysfunction in early-onset IBD through molecular and cellular analyses to uncover patient-specific phenotypes and potential therapeutic targets.

Our previous studies of adult Crohn's disease (CD) suggested ileal microvillus length (MVL) as a prognostic biomarker for therapy response. We investigated if ileal MVL also differed in pediatric CD versus controls and tested for associations with stricturing or penetrating disease behavior outcomes.

While cancer risk is elevated in inflammatory bowel disease (IBD), results are less clear for cervical cancer. Screening has made cervical cancer relatively preventable, but geography impacts access, possibly increasing rates of cancer in rural and remote areas. We investigated (1) odds of cervical cancer, (2) cervical cancer screening participation, and (3) impact of geography (eg, rurality) and immunosuppression on the odds of cervical cancer and cervical cancer screening participation in the IBD population in Alberta, Canada.

We studied the mucosal bacterial population in patients with active Crohn's disease and intestinal tuberculosis. Significant differences were noted in the composition and predicted function of the gut microbiota between the two conditions. Microbial dysbiosis was more severe in intestinal tuberculosis than in Crohn's disease and could differentiate between the two conditions with good accuracy.

The intestinal mucosal barrier plays an important role in the pathophysiology of inflammatory bowel disease (IBD), with mucins being key components of this barrier. Classified as either transmembrane or secreted, these highly glycosylated proteins protect the mucosal barrier while also influencing barrier integrity. Given their indispensable role in maintaining the intestinal mucosal barrier, mucins are compelling candidates for the evaluation of barrier dysfunction. Numerous studies have investigated mucins in the context of IBD, but a clear consensus regarding their expression, polymorphisms, and post-translational modifications is missing. This systematic review summarizes mucin alterations at the transcriptional, translational, and post-translational levels in the presence/absence of intestinal inflammation in IBD patients.